Press Release Archive

August 8, 2012 - Pfizer Reduces Its Greenhouse Gas Emissions by 20 Percent

(BUSINESS WIRE)--Pfizer today announced that it achieved its five-year public goal of reducing greenhouse gas (GHG) emissions by 20 percent after only four years. As a result of this effort, the company achieved $85 million in annualized project savings. This milestone marks the second time since 2000 that Pfizer has reached its target of cutting GHG emissions. ”Environmental sustainability is aligned with Pfizer’s strategic business imperatives,more...

August 7, 2012 - Pfizer Announces Resolutions with DOJ and SEC Related to Certain International Operations

(BUSINESS WIRE)--Pfizer Inc. today announced it has resolved U.S. Department of Justice (DOJ) and Securities and Exchange Commission (SEC) matters related to certain improper payments in the operations of two of its subsidiaries outside the United States, which Pfizer voluntarily reported to the U.S. government beginning in 2004. To resolve those historical issues, a Pfizer indirect subsidiary (Pfizer H.C.P. Corporation) will enter into a deferred prosecutionmore...

August 6, 2012 - Pfizer Announces Co-Primary Clinical Endpoints Not Met In Second Phase 3 Bapineuzumab Study In Mild-To-Moderate Alzheimer’s Disease Patients Who Do Not Carry The Apoe4 Genotype

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the co-primary clinical endpoints, change in cognitive and functional performance compared to placebo, were not met in the Janssen Alzheimer Immunotherapy R&D LLC (Janssen AI)-led Phase 3 trial of intravenous (IV) bapineuzumab in patients with mild-to-moderate Alzheimer’s disease who do not carry the ApoE4 (apolipoprotein E epsilon 4) genotype (Study 301). Pfizer and Janssen AI are partnersmore...

August 6, 2012 - Summertime Shines a Light on the Need for Vitamin D

(BUSINESS WIRE)--This August, up to 51 percent of Americans will take a summer vacation, but many women will take steps to shield themselves from the sun’s harmful ultraviolet (UV) rays. Direct exposure to sunlight is the primary source of vitamin D, an essential nutrient that maximizes the body’s absorption of calcium and helps support healthy bones, joints and muscles.* However, as the body ages, it becomes less efficient at producing vitamin D from themore...

August 2, 2012 - Study Shows Toviaz Is Effective In Reducing Urge Urinary Incontinence In Patients With Overactive Bladder After Suboptimal Response To Detrol LA

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that a Phase 4 study assessing the efficacy and safety of Toviaz® (fesoterodine fumarate) in patients with overactive bladder (OAB) met its primary endpoint. Toviaz reduced urge urinary incontinence (UUI) in patients with OAB who had a suboptimal response (less than 50 percent reduction in UUI) to Detrol LA (tolterodine tartrate extended release), a commonly-prescribed treatment for the condition. UUI ismore...

July 31, 2012 - Pfizer Announces Positive Top-Line Results From The ORAL Start Phase 3 Study Of Tofacitinib In Rheumatoid Arthritis

(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today top-line results from ORAL Start (A3921069), a Phase 3 study of the investigational agent tofacitinib, a novel, oral Janus kinase (JAK) inhibitor for the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA). ORAL Start, an ongoing two-year study in methotrexate (MTX)-naïve patients with moderate-to-severe active RA, randomized to receive tofacitinib 5 or 10 mg twice-daily (more...

July 30, 2012 - Pfizer Reports Second-Quarter 2012 Results

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE): ($ in millions, except per share amounts) Second-Quarter Year-to-Date 2012more...

July 23, 2012 - Pfizer Announces Topline Results Of First Of Four Studies In Bapineuzumab Phase 3 Program

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the co-primary clinical endpoints, change in cognitive and functional performance compared to placebo, were not met in the Janssen Alzheimer Immunotherapy R&D LLC (Janssen AI)-led Phase 3 trial of intravenous (IV) bapineuzumab in patients with mild-to-moderate Alzheimer’s disease who carry the ApoE4 (apolipoprotein E epsilon 4) genotype (Study 302). Pfizer and Janssen AI are partners in themore...

July 22, 2012 - Pfizer Reports Top-Line Results of EU Post-Authorization Safety and Efficacy Study of Lyrica’s Discontinuation Effects In Patients with Generalized Anxiety Disorder

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that top-line results for Lyrica® (pregabalin) capsules Study A0081147 – Long Term Safety and Efficacy of Pregabalin in Subjects with Generalized Anxiety Disorder (GAD) – demonstrate that drug discontinuation symptoms were low after tapering Lyrica treatment following three months and six months in GAD patients. The European Medicines Agency (EMA) requested this study to investigate themore...

July 22, 2012 - Pfizer Reports Top-Line Results of Study of Lyrica’s Effect on Male Reproduction Conducted as a Post-Approval Commitment Required by the U.S. Food and Drug Administration

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that top-line results for Lyrica® (pregabalin) capsules CV Study A0081104 – Assessment of the Impact of Lyrica on Sperm Production in Healthy Volunteers – demonstrate that Lyrica does not affect the reproductive function in healthy males when compared to placebo.1 The study was conducted as a post-approval commitment required by the US Food and Drug Administration (FDA).1 Pfizer will continue to furthermore...

July 19, 2012 - Pfizer’s Crizotinib Receives Positive Opinion For Conditional Marketing Authorization From The Committee For Medicinal Products For Human Use For The Treatment Of Adults With Previously Treated ALK-Positive Advanced Non-Small Cell Lung Cancer In The EU

(BUSINESS WIRE)--Pfizer announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that crizotinib be granted conditional marketing authorization in the European Union (EU), for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). Similar to accelerated approvals in themore...

July 19, 2012 - Pfizer and Northwestern University Win LYRICA® Patent Case in Delaware District Court

(BUSINESS WIRE)--Pfizer Inc. announced today that the United States District Court for the District of Delaware upheld its composition of matter patent and pain and seizure use patents covering LYRICA® (pregabalin) capsules CV. With this decision, Pfizer will exclusively provide pregabalin as LYRICA to patients through December 30, 2018 in the U.S., pending generic company appeal and further litigation. “The Court’s decision recognizes the infringementmore...

July 18, 2012 - European Medicines Agency Accepts Regulatory Submission For Bazedoxifene/Conjugated Estrogens For The Treatment Of Symptoms Associated With Menopause And Osteoporosis

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for bazedoxifene/conjugated estrogens (BZA/CE), a potential new medicine for postmenopausal women with a uterus for the treatment of estrogen deficiency symptoms and treatment of osteoporosis in women at risk of fracture. Pfizer expects a decision from the European Commission in 2013.

June 28, 2012 - Pfizer Declares A 22-Cent Third-Quarter 2012 Dividend

(BUSINESS WIRE)--The board of directors of Pfizer Inc. (NYSE: PFE) today declared a 22-cent third-quarter 2012 dividend on the company’s common stock, payable September 5, 2012, to shareholders of record at the close of business on August 3, 2012. The third-quarter 2012 cash dividend will be the 295th consecutive quarterly dividend paid by Pfizer. more...

June 26, 2012 - Pfizer Invites Public to View and Listen to Webcast of July 31 Conference Call with Analysts

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, July 31, 2012. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2012 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer

June 24, 2012 - Bristol-Myers Squibb and Pfizer Receive Complete Response Letter from U.S. Food and Drug Administration for ELIQUIS® (apixaban)

(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for ELIQUIS® (apixaban) for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. The CRL requests additional information on data management and verification from themore...

June 21, 2012 - EMA Adopts Opinion On Taliglucerase Alfa Marketing Authorization Application

(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX, TASE:PLX) today announced that the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has adopted an Opinion recommending against the Marketing Authorization of taliglucerase alfa, an enzyme replacement therapy (ERT) for the treatment of Gaucher disease. As part of its Opinion, the CHMP gave a positive risk-benefit assessment formore...

June 20, 2012 - FDA Approves Lyrica For The Management Of Neuropathic Pain Associated With Spinal Cord Injury Based On Priority Review

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) approved the use of Lyrica® (pregabalin) capsules CV for the management of neuropathic pain associated with spinal cord injury. Lyrica received a priority review designation for this new indication from the FDA. More than 100,000 patients – approximately 40 percent of the 270,000 patients with spinal cord injury in the United States - suffer from thismore...

June 20, 2012 - Pfizer Statement Regarding Prevnar 13® Receiving ACIP Recommendation for Prevention of Pneumococcal Disease in Adults With Immunocompromising Conditions

(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) issued the following statement in response to today’s Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) vote to recommend the use of Pfizer’s Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) for adults 19 years of age and older with immunocompromising conditions. The ACIP defines immunocompromised as those people who have functional ormore...

June 18, 2012 - Pfizer Announces Positive Results From Phase 3 Study PROFILE 1007 Evaluating XALKORI® (crizotinib) In Previously Treated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer

(BUSINESS WIRE)--Pfizer Inc. announced today that the PROFILE 1007 study met its primary endpoint, demonstrating that XALKORI® (crizotinib) significantly improved progression-free survival (PFS) when compared with pemetrexed or docetaxel, in previously treated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). PROFILE 1007 is the first randomized Phase 3 study in ALK-positive advanced NSCLC patientsmore...

Press release archive foot note

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

Stay on top of Pfizer breaking news: Get News Alerts by RSS.

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

If you do not have Adobe^® Reader, download it here. It is available without charge from Adobe^®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.